Ayman Al-Hendy to Gonadotropin-Releasing Hormone
This is a "connection" page, showing publications Ayman Al-Hendy has written about Gonadotropin-Releasing Hormone.
Connection Strength
1.962
-
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
Score: 0.754
-
Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) - protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open. 2024 01 12; 14(1):e078989.
Score: 0.220
-
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.
Score: 0.214
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
Score: 0.192
-
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
Score: 0.188
-
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
Score: 0.167
-
Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 02; 13(2):169-177.
Score: 0.145
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
Score: 0.043
-
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
Score: 0.038